Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005-2019
To assess the incidence, clinical, microbiological features and outcome of invasive Streptococcus agalactiae (GBS) infections in non-pregnant adults in three tertiary hospitals of the Brussels-Capital Region. All bacterial cultures positive for GBS, from 2005 to 2019 from 3 hospitals of the Brussels-Capital Region, were extracted, and only cases of invasive diseases were included. Medical files were retrospectively retrieved for risk factors, clinical manifestations and outcome and also antibiotic-susceptibility testing and GBS serotypes. Incidence rates were calculated based on the hospitals catchment populations. A total of 337 cases of GBS-invasive infections were included. The incidence of invasive GBS for the 3 hospitals increased from 3.7 to 8.2 cases per 100.000 inhabitants between 2009 and 2018 (p = 0.04). The most frequently identified risk factors were diabetes (36.8%), obesity (35.0%), cancer (21.7%), renal disease (20.8%), and advanced age (≥ 65 years; 47.2%). Isolated bacteremia (22%), osteoarticular infection (21.4%), abscesses (13.9%), and skin and soft tissue infections (18.4%) were the most frequent manifestations. Intensive care unit admission was required in 21.7% and overall mortality was 9.4%. All strains remained susceptible to penicillin over the years. Up to 20% of strains were resistant to clindamycin. Serotypes Ia, Ib, II, III, IV, and V represented 96.8% of the available serotypes (60/62). As reported in several countries, invasive GBS disease in non-pregnant adults represents an increasing burden, particularly among diabetic, obese, and elderly patients. Almost all serotypes identified are included in the upcoming hexavalent GBS conjugate vaccine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 40(2021), 3 vom: 17. März, Seite 515-523 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Graux, Elena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 04.08.2021 Date Revised 04.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10096-020-04041-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315163739 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315163739 | ||
| 003 | DE-627 | ||
| 005 | 20231225154320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-020-04041-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315163739 | ||
| 035 | |a (NLM)32944894 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Graux, Elena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005-2019 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2021 | ||
| 500 | |a Date Revised 04.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To assess the incidence, clinical, microbiological features and outcome of invasive Streptococcus agalactiae (GBS) infections in non-pregnant adults in three tertiary hospitals of the Brussels-Capital Region. All bacterial cultures positive for GBS, from 2005 to 2019 from 3 hospitals of the Brussels-Capital Region, were extracted, and only cases of invasive diseases were included. Medical files were retrospectively retrieved for risk factors, clinical manifestations and outcome and also antibiotic-susceptibility testing and GBS serotypes. Incidence rates were calculated based on the hospitals catchment populations. A total of 337 cases of GBS-invasive infections were included. The incidence of invasive GBS for the 3 hospitals increased from 3.7 to 8.2 cases per 100.000 inhabitants between 2009 and 2018 (p = 0.04). The most frequently identified risk factors were diabetes (36.8%), obesity (35.0%), cancer (21.7%), renal disease (20.8%), and advanced age (≥ 65 years; 47.2%). Isolated bacteremia (22%), osteoarticular infection (21.4%), abscesses (13.9%), and skin and soft tissue infections (18.4%) were the most frequent manifestations. Intensive care unit admission was required in 21.7% and overall mortality was 9.4%. All strains remained susceptible to penicillin over the years. Up to 20% of strains were resistant to clindamycin. Serotypes Ia, Ib, II, III, IV, and V represented 96.8% of the available serotypes (60/62). As reported in several countries, invasive GBS disease in non-pregnant adults represents an increasing burden, particularly among diabetic, obese, and elderly patients. Almost all serotypes identified are included in the upcoming hexavalent GBS conjugate vaccine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Group B Streptococcus | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a Invasive infections | |
| 650 | 4 | |a Non-pregnant adults | |
| 650 | 4 | |a Obesity | |
| 650 | 4 | |a Serotypes | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Hites, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Martiny, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Maillart, Evelyne |e verfasserin |4 aut | |
| 700 | 1 | |a Delforge, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Melin, Pierrette |e verfasserin |4 aut | |
| 700 | 1 | |a Dauby, Nicolas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 40(2021), 3 vom: 17. März, Seite 515-523 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2021 |g number:3 |g day:17 |g month:03 |g pages:515-523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-020-04041-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2021 |e 3 |b 17 |c 03 |h 515-523 | ||